icon-folder.gif   Conference Reports for NATAP  
 
  EASL 48th Annual Meeting
April 24th - 28th 2013
The Netherlands, Amsterdam
Back grey_arrow_rt.gif
 
 
 
Sofosbuvir Safety and Tolerability in 778 Patients Treated for Up to 24 Weeks in Four Phase 2 Studies
 
 
  Reported by Jules Levin
EASL 2013 April 24-28 Amsterdam
 
Kris V. Kowdley1, Tarek Hassanein2, Edward J. Gane3, Robert H. Hyland4, Julie Ma4, William T. Symonds4, Jay Lalezari5, Eric Lawitz6
1Virginia Mason Medical Center, Seattle, WA, USA: 2Southern California Liver Center, Coronado, CA, USA; 3New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand;
4Gilead Sciences, Inc., Foster City, CA, USA; 5Quest Clinical Research, San Francisco, CA, USA; 6Texas Liver Institute, San Antonio, TX, USA

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif